CSPG4 and astrocytic tumor: The relationship between NG2/CSPG4 immunoreactivity and overall survival OS was analyzed in two tumor sub-groups, including 18 oligodendroglial tumors (ten grade II and eight grade III) and 24 astrocytic tumors (seven grade II, two grade III, and 15 GBs).